REGULAR SUBMISSION

EULAR 2027 | REGULAR SUBMISSION

Regular Abstract submission is open from 1 October 2026 until 15 January 2027. Online publication of accepted abstracts will be approximately two weeks prior to the congress.

Please read all the instructions carefully before preparing and submitting your abstract.

Abstracts can be re-edited and modified until the submission deadline. After the submission deadline, no modification will be accepted by the EULAR team.

Each abstract must be assigned one of the following tracks, one of the following topics and between two and five of the abstract keywords.

TRACKS

'Basic’ research is the hypothesis-driven and systematic study of a disease or topic in order to broaden the knowledge base and our understanding of that topic. Basic research typically provides the basis evidence in the form of observations and facts, but do not have specific processes or products in mind.

‘Translational’ research refers to several stages which aims to progress the findings of basic research. The first stage bridges the gap between Basic Science and Clinical Research. This stage of translational research advances the findings of basic science by designing and implementing studies to examine previously findings in models without direct implementation in humans; this could be cell cultures or animal models, or even computer simulations. Further stages of Translational research aim to implement these initial ‘pre-clinical’ findings into controlled studies investigating patient populations, and beyond that, into widespread clinical trials and care, and, ultimately, into population-level research.

If your research focuses on any of these above areas, we welcome the submission of your abstract in the appropriate topic within the Basic and Translational Track:

TOPICS

Antiphospholipid syndrome
Autoinflammatory disease, VEXAS and other monogenic diseases
Behcet's disease
Crystal related disorders
Immunodeficiency
Infection
Infection-related rheumatic diseases
Inflammatory arthritis
Inflammatory myopathies
Juvenile idiopathic arthritis
Metabolic bone diseases and osteoporosis
Mixed connective tissue disease
Osteoarthritis and other mechanical musculoskeletal problems
Other connective tissue diseases
Pain in rheumatic diseases, including fibromyalgia
Psoriatic arthritis
Public and global health
Rheumatoid arthritis
Sarcoidosis
Sjögren's disease
Spondyloarthritis
Systemic lupus erythematosus
Systemic sclerosis
Vasculitis, small and medium size vessels
Vasculitis, large vessels including polymyalgia rheumatica
Across diseases
Other diseases
Other topics

KEYWORDS

Adaptive immunity; Aging; Animal Models; Anti-Inflammatory Agents, Non-Steroidal; Artificial Intelligence; Atherosclerosis; Autoantibodies; Autoimmunity; biological DMARD; Biomarkers; Biosimilar Pharmaceuticals; Bone; Cardiovascular system; CAR-T; Cartilage; Clinical Trial; Cognitive Function and Mental Health; Comorbidities; Cytokines and Chemokines; Descriptive Studies; Diagnostic test; Diet and Nutrition; Disease-modifying Drugs (DMARDs); Diversity, Equity, and Inclusion (DEI); Economics; Education; Enthesitis; Epidemiology; Epitranscriptomics, epigenetics, and genetics; Fatigue; Fibroblasts; Gastrointestinal tract; Geographical differences; Global Health; Glucocorticoids; Health services research; Imaging; Infection; Innate immunity; Interdisciplinary research; Lifestyles; Lungs; Magnetic Resonance Imaging; Microbiome; Non-pharmacological interventions; Nursing; Observational studies/registries; Occupational therapy; -omics; Oncology; Outcome measures; Pain; Patient organisations; Patient Reported Outcome Measures; Patient-led research; Physical therapy, Physiotherapy, and Physical Activity; Pregnancy and reproduction; Prognostic factors; Public health; Qualitative research; Quality of care; Quality of life; Randomised controlled trial; Rare/orphan diseases; Real-world evidence; Rehabilitation; Remission; Renal System; Safety; Sarcopenia; Self-management; Skin; Social work; Synovium; Systematic review; T-Cell Engagers; Tapering; Targeted synthetic drugs; Telemedicine, digital health, and measuring health; Ultrasound; Uveitis; Vaccination/Immunisation; Validation; Women's Health; Work-related issues.

FORMAT AND LENGTH

Abstract title: minimum 15 characters, maximum 300 characters

Total limit: 6,000 characters, including spaces.

Table and figures: A maximum of any two figures, graphs, images or tables is allowed per abstract, e.g. 1 graph and 1 table, or 2 graphs, or 2 images. Multi-panel figures are allowed. Please see below for guidance on including tables.

Abstracts with one or more tables should not have more than 12 columns or 20 rows. Tables turned into pictures/images are accepted, but they should have sufficient quality that everything is readable. Data in images cannot be edited after the abstract has been accepted.

Abstract content is to be inputted directly into the portal in the sections listed below. Note that, in response to your feedback, we no longer use the downloadable word template seen in previous years. If pasting directly into the portal, please ensure that you paste as plain text to ensure no formatting errors. Please read all instructions carefully before preparing your abstract.

Characters counting towards the 6000 characters (with spaces) for Regular Submissions:

All content of the abstarct itself, inputted by the submitter. This includes:

Background
Objectives
Methods
Results
Conclusions
Image 1 and 2 (optional): Any text typed or pasted directly into the text box counts toward the character limit. If the field is used for uploading .jpg or .png files, it does not count.
References (optional)

Characters not counting towards the 6000 characters (with spaces), but part of final abstract:

All other information, not in the body of the abstract itself. This includes:

Abstract title (minimum 15, maximum 300 characters)
Author first names, middle initials, and last names
Author affiliations
Acknowledgements
Working group + "on behalf of" if entered
Abstract number
COI (Declaration of conflict of interest)
Content headings
Files uploaded as .jpg or .png in the sections "Image 1" and "Image 2"

‘Clinical’ research explores whether new treatments, medications, devices, and diagnostic techniques and tool are safe, efficacious, and/or cost-effective. Clinical research may take the form of intervention studies (clinical trials) or observational studies, such as case-control, cross-sectional, or longitudinal studies. Where Basic and Translational research is commonly lab-based, clinical research is done in living human volunteers, either healthy or with a specific condition or disease.

If your research focuses on any of these above areas, we welcome the submission of your abstract in the appropriate topic within the Clinical Research Track:

TOPICS

Antiphospholipid syndrome
Autoinflammatory disease, VEXAS and other monogenic diseases
Behcet's disease
Crystal related disorders
Immunodeficiency
Infection
Infection-related rheumatic diseases
Inflammatory arthritis
Inflammatory myopathies
Juvenile idiopathic arthritis
Metabolic bone diseases and osteoporosis
Mixed connective tissue disease
Osteoarthritis and other mechanical musculoskeletal problems
Other connective tissue diseases
Pain in rheumatic diseases, including fibromyalgia
Psoriatic arthritis
Public and global health
Rheumatoid arthritis
Sarcoidosis
Sjögren's disease
Spondyloarthritis
Systemic lupus erythematosus
Systemic sclerosis
Vasculitis, small and medium size vessels
Vasculitis, large vessels including polymyalgia rheumatica
Across diseases
Other diseases
Other topics

KEYWORDS

FORMAT AND LENGTH

Abstract title: minimum 15 characters, maximum 300 characters

Total limit: 6,000 characters, including spaces.

The EULAR HPR (Health Professionals in Rheumatology) community is the network of national organisations of HPR across Europe. It serves as platform for clinical, scientific, and educational activities, collaboration and shared information among the different health professionals working within rheumatology. HPR forms one of EULAR’s three pillars and includes a diverse group of people and professions, including therapeutic and diagnostic professions, epidemiologists and statisticians, and various other professions such as pharmacists and social workers. Medical doctors and people with RMDs are included in EULAR’s other pillars.

Here is a list of different professions included in the HPR pillar (this list is not exhaustive)

Dietician or nutritionist
Epidemiologist & Statistician
Kinesiologist (provided other criteria are met)
Nurse
Occupational therapist
Orthotist and Prosthetist
Pharmacist
Physical therapist or physiotherapist
Physician’s assistant
Podiatrist
Psychologist
Radiographer
Social worker
Sports Scientist

If you are a healthcare professional affiliated with the HPR pillar, as outlined above, or if your abstract presents research conducted under the HPR, you may submit your abstract to the appropriate subcategory within the HPR track (C). The HPR topics are:

TOPICS

29. HPR Measuring health
30. HPR Epidemiology and public health
31. HPR Interventions
32. HPR Patients' perspectives
33. HPR Implementation and service evaluation
34. HPR Professional education, training and competencies

KEYWORDS

FORMAT AND LENGTH

Abstract title: minimum 15 characters, maximum 300 characters

Total limit: 6,000 characters, including spaces.

The EULAR PARE (People with Arthritis/Rheumatism in Europe) community is the network of national organisations of people living with rheumatic and musculoskeletal diseases (RMDs) and their support networks. The PARE community is united to ensure the voice of people living with RMDs is heard and has influence among decision makers within Europe, creating powerful alliances that will make a difference to their lives.

PARE forms one of EULAR’s three pillars and includes people living with RMDs and their support networks (as indicated below). Medical doctors and health professionals in rheumatology are included in EULAR’s other pillars.

Here are the different individuals associated with the PARE pillar:

People living with RMDs
Carers (including friends and family members) of people living with RMDs
Patient organisations (at every level, from support groups to medical charities)

We encourage the submission of abstracts to the PARE track (D) that showcase activities and research from the patient and carer perspective, as well as broader abstract topics of direct relevance to the PARE community.

TOPICS

35.   PARE Patient information and education
36.   PARE Patient involvement in research
37.   PARE RMD research
38.   PARE Innovations in RMD health care and support
39.   PARE Psychosocial support
40.   PARE Work and rehabilitation
41.   PARE Best practices

KEYWORDS

FORMAT AND LENGTH

Abstract title: minimum 15 characters, maximum 300 characters

Total limit: 6,000 characters, including spaces.

Start with the customer – find out what they want and give it to them.

HOW TO INCLUDE TABLES

Tables can only be inserted in the Image, graphic, or table section. There are two ways to include a table: you can either create a table from scratch in the portal, or paste a table from an external source, such as Word or Excel. Both methods are allowed, and following these steps will help ensure your table is correctly formatted and ready for submission.

Creating a table from scratch:

1. In the Image, graphic, or table section, click on the table icon in the menu bar and select the desired table size.

2. Your table has now been created. Enter your text, and use the menu bar settings to adjust the table layout (add or remove rows and columns).

3. From the table dropdown menu, you can further customise your table, for example by merging cells or changing cell margins.

4. Your table is now ready for submission.

Pasting a table from an external source

1. Copy the entire table from your external source (e.g., Word or Excel), click into the Image, graphic, or table section, and paste your table.

2. When a table is inserted, the cell lines are initially displayed as dashed lines. These lines are not visible in the final abstract. To make the cell lines visible, click Advanced in the Cell Properties window. In Border style, choose Solid and select a Border colour. Save your settings.

3. Your table is now ready for submission.

General Information

Back to the top

Not yet available.